

NIKS PROFESSIONAL LTD. Clinics . Shops . Salons . Medical Skincare Products

Annual General Meeting FY2024

23 April 2025



Disclaimer

This presentation is for information purposes only and does not constitute or form part of an offer, solicitation, recommendation or invitation for the sale or purchase or subscription of securities in Niks Professional Ltd.. No part of it nor the fact of its presentation shall form the basis of or be relied upon in connection with any investment decision, contract or commitment whatsoever.

The information and opinions in this presentation are provided as at the date of this document (unless stated otherwise) and are subject to change without notice, their accuracy are not guaranteed, represented or warranted and they may not contain all material or relevant information concerning the Company or the Company and its subsidiaries (collectively, the "Group"). Neither the Company nor its related corporations, affiliates, nor any of their respective directors, officers, partners, employees, agents, representatives or advisers make any representation or warranty regarding, and assumes no responsibility, obligation or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of this presentation. Further, nothing in this presentation should be construed as constituting legal, business, tax, investment or financial advice.

The information contained in this presentation includes historical information about and relevant to the Group or the Group's businesses that should not be regarded as an indication of the future performance or results of the Group or such businesses. Certain statements in this presentation constitute "forward-looking statements". These forward-looking statements are based on the current views of the Group concerning future events, and necessarily involve risks, uncertainties and assumptions, which may change over time. These statements can be recognised by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends" or words of similar meaning. Actual future performance could differ materially from these forward-looking statements, and no assurance is given that future events will occur, that projections will be achieved, or that the Group's views are correct, nor should you rely on these forward-looking statements for any purpose. The Company does not assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise, subject to compliance with all applicable laws and regulations and/or the rules of the Singapore Exchange Securities Trading Limited and/or any other regulatory or supervisory body or agency.



FY2024 Highlights



Opening of Niks Maple North Clinic

- New clinic at 926 Yishun Central 1 #01-175 Singapore 760926 commenced operations in August 2024
- Equipped with DiscoveryPICO laser machine and Inmode Contoura machine (for skin tightening and body contouring treatment)



Technology-enabled skincare treatment

- Our range of medical equipment is updated regularly to enable our doctors to provide quality treatment
- Acquired machines to enhance capabilities and expand service offerings e.g. TruScript ID (non-invasive body sculpting), Tricopat (treat hair thinning concerns), Classys Ultraformer MPT (combat wrinkles, droopy eyelids, uneven skin tone), Reborn system (fat reduction and body contouring) and the 7th Generation VISIA Skin Analysis System (skin type classification)



Expanded sales channels

- Established new regional distributorship in Guangdong, Hunan and Anhui provinces of China
- Set up new online shops in the following ecommerce platforms; Tmall in China; and Shopee and Lazada in Singapore
- Opened new account in social media and ecommerce platform, Rednote (Xiaohongshu) in April 2024 (Launched online shop in February 2025)

NIK PROFESSIONAL LTD.



REVENUE By Business Segments



	FY2024 S\$'000	%	FY2023 S\$'000	%	
Clinics	6,868	61	6,808	63	
Retail	2,211	20	2,216	20	
Headquarters (HQ)	2,111	19	1,830	17	<u> </u>
Total	11,190	100	10,854	100	

Increase was mainly attributable to sales to new regional agents in China, sales generated from new online store at Tmall and higher volume of sales generated from online store at the Company's website.





Revenue By Country and Products/ Services

Profit & Loss Highlights



¹ Gross profit margin on product sales are 80% and 81% for FY2024 and FY2023 respectively.



Consolidated Statement of Comprehensive Income

	FY2024	FY2023	Change 97
	\$\$'000		Change %
Revenue	11,190	10,854	3.1
Cost of goods sold	(1,814)	(1,618)	12.1
Employee benefits expense	(5,033)	(4,768)	5.6
Depreciation	(1,023)	(740)	38.2
Other expenses	(1,224)	(2,099)	(41.7)
Interest income and finance costs	132	134	NM
Other income and gains	301	577	(47.8)
Other losses	(43)	(111)	(61.3)
Profit before tax	2,486	2,229	11.5
Income tax expense	(407)	(488)	(16.6)
Net profit	2,079	1,741	19.4
Profit attributable to shareholders	2,079	1,686	23.3
Earnings per share (cents)*	1.6	1.3	

Increase was due to salary increment and increase in headcount, such as hiring of a doctor, a deputy general manager (Sales and marketing), clinic assistants in new clinic and warehouse/ logistics staff.

Increase was mainly due to addition of medical equipment, computers, renovation and ROU assets since July 2023.

Decrease was mainly due to absence of IPO-related expenses (FY2023: S\$1,088k) and reduction of rental expenses. These decreases were partially offset by increases in listing expenses, professional fees, Advertising and marketing expenses and foreign workers' levy.

Decrease was mainly due to lower government grant income. During FY2023, a one-time \$\$300k grant (GEMS) relating to the Company's IPO was recognised.

Decrease was mainly due to lower amount of allowance for impairment of inventories recognised in FY2024.

<u>Notes</u> NM – Not meaningful * Based on 130,000,000 ordinary shares



Consolidated Statement of Financial Position

Balance Sheet Highlights

\$\$'000	As at 31 Dec 2024	As at 31 Dec 2023
Non-Current Assets (excl. leasehold properties)	2,705	1,789
3 leasehold properties owned by the Company	9,183	9,327
Current Assets (excl. cash and cash equivalents)	2,423	2,428
Cash and Cash Equivalents	9,180	9,086
Non-Current Liabilities	(972)	(912)
Current Liabilities	(2,343)	(2,336)
Equity Attributable to Owners	20,176	19,382
Net asset value per share (cents)*	15.5	14.9

-	Mainly comprise plant and equipment
	Fully paid properties used for clinic and retail operations
	Ang Mo Kio and Bedok HDB shophouses housing Niks Shop Salons (acquired in Nov 2019 and April 2017 respectively)
	Vision Exchange property housing Niks Maple West Clinic (acquired in Dec 2017)
	Healthy cash position. Company has no bank loans.
	Mainly comprise lease liabilities relating to office, warehouse, clinic and retail premises
	Mainly comprise trade and other payables, lease liabilities and income tax payable

* Based on 130,000,000 ordinary shares



Statement of Cash Flows

Cash Flow Highlights

\$\$'000	FY2024	FY2023	
Net cash from operating activities	2,561	2,193	Recurring operating cash flows
Net cash used in investing activities	(547)	(169)	Comprised purchase of property, plant are equipment, partially offset by interest rece
Net cash used in financing activities	(1,964)	(5,308)	Mainly comprised dividends and lease liak paid. Amount was high for FY2023 due to IPO dividend paid which was partially offse
Net increase/ (decrease) in cash and cash equivalents	50	(3,284)	IPO proceeds
Cash and cash equivalents, ending balance	9,180	9,086	





Dividends

Annual General Meeting FY2024

Dividend type	Final; Tax exempt (1-tier)
Total number of issued ordinary shares	130,000,000
Dividend per share (cent)	1.0
Total dividend (S\$'000)	1,300
Dividend Payout	63% of net profit attributable to shareholders for FY2024
Record/ Payment date	To be announced later

Plans for FY2025





and the younger

consumers



Telephone: +65 6294 1802 | Email: ir@nikspro.com

THANK YOU

TIC DERMATOLOGY

ies • Celebrated pioneers